MiNK Therapeutics Announces Confidential Submission of Draft Registration Statement for Proposed Initial Public Offering
July 28 2021 - 8:30AM
MiNK Therapeutics today announced that it has confidentially
submitted a draft registration statement on Form S-1 with the
Securities and Exchange Commission (the "SEC") relating to the
proposed initial public offering of its common stock. The number of
shares to be offered and the price range for the proposed offering
have not yet been determined. The initial public offering is
expected to take place after the SEC completes its review process,
subject to market and other conditions. MiNK is a subsidiary of
Agenus Inc. (NASDAQ: AGEN).
This press release is being made pursuant to, and in accordance
with, Rule 135 under the Securities Act of 1933, as amended (the
"Securities Act"), and shall not constitute an offer to sell, or
the solicitation of an offer to buy, any securities. Any offers,
solicitations or offers to buy, or any sales of securities will be
made in accordance with the registration requirements of the
Securities Act.
ContactAgenus Investor
RelationsJan Medina,
CFAAgenus781-674-4490Jan.Medina@agenusbio.com
Agenus Media RelationsKimberly HaKKH
Advisors917-291-5744kimberly.ha@kkhadvisors.com
Agenus (NASDAQ:AGEN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Agenus (NASDAQ:AGEN)
Historical Stock Chart
From Sep 2023 to Sep 2024